Journal article
Effect of Minimally Invasive Surfactant Therapy vs Sham Treatment on Death or Bronchopulmonary Dysplasia in Preterm Infants with Respiratory Distress Syndrome: The OPTIMIST-A Randomized Clinical Trial
PA Dargaville, COF Kamlin, F Orsini, X Wang, AG De Paoli, HG Kanmaz Kutman, M Cetinkaya, L Kornhauser-Cerar, M Derrick, H Özkan, CV Hulzebos, GM Schmölzer, A Aiyappan, B Lemyre, S Kuo, VS Rajadurai, J O'Shea, M Biniwale, R Ramanathan, A Kushnir Show all
JAMA | Published : 2021
Abstract
Importance: The benefits of surfactant administration via a thin catheter (minimally invasive surfactant therapy [MIST]) in preterm infants with respiratory distress syndrome are uncertain. Objective: To examine the effect of selective application of MIST at a low fraction of inspired oxygen threshold on survival without bronchopulmonary dysplasia (BPD). Design, Setting, and Participants: Randomized clinical trial including 485 preterm infants with a gestational age of 25 to 28 weeks who were supported with continuous positive airway pressure (CPAP) and required a fraction of inspired oxygen of 0.30 or greater within 6 hours of birth. The trial was conducted at 33 tertiary-level neonatal int..
View full abstractGrants
Awarded by Medtronic
Funding Acknowledgements
This study was funded by grant 11-382 from the Royal Hobart Hospital Research Foundation and by grant 1049114 from the Australian National Health and Medical Research Council. Chiesi Farmaceutici provided the exogenous surfactant at reduced cost.